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The pharmacological properties of natural compounds have garnered increasing attention in the field of alterna-
tive and coadjuvant therapeutic approaches to cardiovascular 
diseases.1 Currently, the food industry is focused on bioactive 
molecules contained in foods or natural matrices, which, be-
sides their nutritional value, can bring health benefits, espe-
cially in the treatment of chronic diseases.2 Moreover, these 
compounds are characterized by fewer side-effects in com-
parison with pharmacological therapies, so consumers tend to 
prefer their use for health promotion.
The dried biomass of the cyanobacterium Spirulina platen-
sis, known as spirulina, is rich in bioactive compounds.3 such 
as essential amino acids, carotenoids, vitamins, polyunsaturated 
fatty acids, and protein,4 and is considered a superfood of the 
future. Interestingly, spirulina has been reported to exert biolog-
ical activities and have beneficial properties in the management 
of cardiovascular diseases.5 Thus, the identification of novel 
bioactive peptides from this natural source could be useful in 
developing alternative therapeutic tools for reducing, or even 
preventing, cardiovascular diseases. On this point, simulated 
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Abstract—Considered as a superfood of the future, Spirulina platensis matrix has been extensively used because of 
its beneficial effect on the management of cardiovascular diseases. However, its nutraceutical properties, bioactive 
compounds, and molecular mechanisms are unknown. Here, we demonstrate that S platensis matrix processed in vitro by 
simulated gastrointestinal digestion induces direct endothelial nitric oxide (NO)-mediated vasorelaxation of resistance 
vessels in mice. To gain insight into the bioactive compounds responsible for this effect, we used a complex multistep 
peptidomic approach to fractionate the crude digest: of the 5 peptide fractions identified (A–E), only fraction E evoked 
vasorelaxation. High-resolution mass spectrometry–based screening revealed in E the presence of 4 main peptides 
(SP3–SP6 [spirulina peptides]), of which only SP6 (GIVAGDVTPI) exerted direct endothelium-dependent vasodilation 
of ex vivo vessels, an effect occurring via a PI3K (phosphoinositide-3-kinase)/AKT (serine/threonine kinase Akt) 
pathway converging on NO release. In vivo, administration of SP6 evoked a significant hemodynamic effect, reducing 
blood pressure, an action absent in eNOS (endothelial NO synthase)-deﬁcient mice. Of note, although lower doses of 
SP6 had no hemodynamic effects, it still enhanced endothelial NO vasorelaxation. Finally, in an experimental model 
of arterial hypertension, SP6 exerted an antihypertensive effect, improving endothelial vasorelaxation associated with 
enhanced serum nitrite levels. Based on our results, this novel decameric peptide may extend the possible fields of 
application for spirulina-derived peptides and could be developed into a promising nonpharmacological approach for 
the containment of pathologies associated with vascular NO misregulation.  (Hypertension. 2019;73:449-457. DOI: 
10.1161/HYPERTENSIONAHA.118.11801.) • Online Data Supplement
Key Words: blood pressure ◼ endothelium ◼ peptides ◼ spirulina ◼ vasodilation
Novel Potent Decameric Peptide of Spirulina platensis 
Reduces Blood Pressure Levels Through a  
PI3K/AKT/eNOS-Dependent Mechanism
Albino Carrizzo, Giulio Maria Conte, Eduardo Sommella, Antonio Damato,  
Mariateresa Ambrosio, Marina Sala, Maria Carmina Scala, Rita Patrizia Aquino,  
Massimiliano De Lucia, Michele Madonna, Francesca Sansone, Carmine Ostacolo,  
Mario Capunzo, Serena Migliarino, Sebastiano Sciarretta, Giacomo Frati, Pietro Campiglia,*  
Carmine Vecchione*
© 2018 American Heart Association, Inc.
Hypertension is available at https://www.ahajournals.org/journal/hyp DOI: 10.1161/HYPERTENSIONAHA.118.11801
Nonpharmacological Treatment
D
ow
nloaded from
 http://ahajournals.org by on August 27, 2019
450  Hypertension  February 2019
human gastrointestinal digestion (GID) of natural matrices 
represents the best method to obtain functional, readily ab-
sorbed bioactive peptides from larger parental proteins.6
Here, we demonstrate for the first time that GID-spirulina 
evokes dose-dependent vasorelaxation of ex vivo mouse re-
sistance vessels: the mechanism identified was a PI3K/AKT 
pathway-dependent one that converged on nitric oxide (NO) 
release. Peptidomic analysis of GID-spirulina identified a 
decameric peptide, herein denominated SP6 (spirulina peptide 
6), whose sequence (GIVAGDVTPI) has never been re-
ported. In vivo administration of SP6 reduced blood pressure, 
improved endothelial vasorelaxation, and exerted an antihy-
pertensive action in experimental models of hypertension, 
working through a NO-dependent mechanism. The identifi-
cation of this novel compound extends the scope of applica-
tions of spirulina-derived peptides, laying the foundation for 
the development of promising nonpharmacological products 
aimed at containing vascular dysfunction associated with mis-
regulation of NO, such as arterial hypertension.
Methods
The data that support the findings of this study are available from 
the corresponding authors on reasonable request. For detailed meth-
odologies, please see the online-only Data Supplement. Simulated 
GID of spirulina was conducted in vitro following Pepe et al.7 The 
peptides in the digest were identified by Orbitrap-mass spectrometry. 
Subsequently, the crude digest was fractionated and the main peptides 
identified by UHPLC-MS/MS (ultra-high performance liquid chroma-
tography–tandem mass spectrometry) and synthesized through F-moc 
protocol. Vascular reactivity studies were performed with a myograph-
based technique on second-order branches of the mesenteric arterial 
tree removed from animals. Vascular precontraction was performed 
administering increasing doses of phenylephrine (10–9–10–6 M) to 
obtain a similar level of precontraction equal to 80% of initial KCl-
induced contraction. Blood pressure was measured using noninvasive 
tail-cuff and invasive in vivo methods. Some vessels obtained for vas-
cular studies were rapidly subjected to protein extraction for molec-
ular studies evaluating total and phosphorylated eNOS (endothelial NO 
synthase), PI3K, and AKT. Another set of vessels was used to measure 
in-situ NO levels by the DAF-FM (4-amino-5-methylamino-2',7-
difluorofluorescein diacetate) technique. Blood samples were used 
to measure nitrite levels on a 280i Nitric Oxide Analyzer (Sievers 
Instruments) and circulating levels of SP6 by UHPLC-MS/MS.
Statistical Analysis
All data are presented as mean±SEM. For continuous variables, 
we used a t test to compare 2 independent groups. When >2 inde-
pendent groups were compared, we used 1-way ANOVA followed 
by Bonferroni post hoc test. To analyze the effects of our treatments 
on endothelium-dependent vasorelaxation in response to increasing 
doses of acetylcholine or SP6, we performed a 2-way repeated-mea-
sures ANOVA with Bonferroni post hoc test for multiple compari-
sons. A P value of <0.05 was considered statistically signiﬁcant. All 
statistical analyses were conducted with Prism statistical software 
(GraphPad, La Jolla, CA).
Results
GID-Spirulina Evokes Dose-Dependent 
Vasorelaxation Through NO Release
Bioactive peptides usually arise from enzymatic hydrolysis 
of their parent proteins. Indeed, in the gastrointestinal tract, 
enzymes digest food proteins to release hundreds of peptides 
that can act either locally or after being absorbed by the body.7 
To mimic the physiological digestion process, we performed 
in vitro GID of spirulina (Figure 1A). Because the resulting 
digest was extremely complex, we employed Orbitrap-based 
mass spectrometry to identify peptide sequences (Figure S1 
in the online-only Data Supplement). A total of 97 peptides 
were identified belonging to phycocyanin (α and β chains) 
and to allophycocyanin (α and β chains; Table S1); mo-
lecular weights spanned from 487 Da (IAGID) to 2084 Da 
(AIVNDPAGITPGDCSALASEIA).
To evaluate whether GID-spirulina exerted any effect 
on vascular function, we exposed ex vivo phenylephrine-
preconstricted mouse mesenteric arteries—a prototype of 
resistance vessel involved in the modulation of blood pres-
sure—to increasing doses (2–200 µg/mL) of GID-spirulina. 
GID-spirulina evoked vasorelaxation in a dose-dependent 
manner, an effect completely abolished by the prior exposure 
of vessels to N(ω)-nitro-L-arginine methyl ester (L-NAME), 
a well-characterized inhibitor of eNOS (Figure 1B). Of note, 
GID-spirulina did not evoke vasorelaxation of vessels that had 
the endothelium mechanically removed, suggesting that endo-
thelial cells are the cellular target (Figure 1C). To confirm that 
eNOS was necessary for GID-spirulina’s effect, we repeated 
the experiments with mesenteric arteries from eNOS-knock-
out mice. Coherently, GID-spirulina failed to induce any dose-
dependent vasorelaxation of these vessels (Figure 1D).
GID-Spirulina-Evoked Vasorelaxation is Mediated 
Through the PI3K/AKT Pathway
To dissect the molecular mechanism involved in GID-
spirulina’s action, we performed another series of experiments 
using Compound C, LY294002, or AKT Inhibitor X, pharma-
cological inhibitors of AMPK, PI3K, and AKT, respectively, 3 
important intracellular molecules involved in NO regulation. 
GID-spirulina was still able to induce dose-dependent vaso-
relaxation in the presence of Compound C (Figure 2A), but 
not in the presence of LY294002 or AKT Inhibitor (Figure 2B 
and 2C), clearly demonstrating that the PI3K/AKT pathway is 
recruited by spirulina. At the molecular level, GID-spirulina–
induced the phosphorylation of PI3K at tyrosine 458 and of 
AKT at serine 473, 2 clear activation markers of these kinases 
that drive eNOS activation by phosphorylation of the enzyme 
at serine 1177. Of note, inhibition of either PI3K or AKT 
blocked phosphorylation of eNOS at serine 1177; moreover, 
when AKT was inhibited, PI3K was still activated (Figure 2D), 
an observation suggesting that PI3K is the upstream modulator.
Fractionation of Crude Spirulina Digest and 
Vascular Evaluation of the Peptide Fractions
In vitro simulated GID employs endogenous peptidases, such 
as pepsin and trypsin, to mimic the physiological process. 
This leads to the hydrolysis of parent proteins into hundreds 
of peptides, resulting in an extremely complex crude digest. 
Thus, we fractionated the crude hydrolysate on the basis of 
hydrophobicity by preparative liquid chromatography. Five 
different fractions (A–E) were obtained (Figure 3A): fraction 
A was discarded because of the absence of peptides, leaving 
fractions B to E to be screened for bioactivity.
Of the 4 fractions studied, only E was capable of evoking 
vasorelaxation of vessels ex vivo, an activity that occurred in a 
dose-dependent manner (Figure 3B); this effect was abolished 
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by pretreatment with L-NAME (Figure 3C). We then tested 
for hemodynamic effects in vivo, administrating a single oral 
dose (10 mg/kg) of each fraction separately to normotensive 
mice. Interestingly, E reduced systolic blood pressure signif-
icantly between 4 and 8 hours postadministration, whereas 
the other fractions had no effect (Figure 3D, left). Vascular 
reactivity studies were then performed on mesenteric arter-
ies excised from mice 4 hours after fractions were adminis-
tered, a time when blood pressure was maximally reduced. 
Only vessels harvested from mice administered fraction E 
had a significantly improved vasorelaxation response to ace-
tylcholine, candidating it as the most vascular bioactive frac-
tion (Figure 3D, right). The administration of lower doses of 
E (5 and 2.5 mg/kg) to mice was not sufficient to modulate 
blood pressure significantly (Figure 3E, left), although they 
were still associated with a significantly improved vascular 
function in harvested mesenteric arteries (Figure 3E, right). In 
line with all prior findings that the effect seen on the vascula-
ture was dependent on intact NO metabolism, administration 
of E did not reduce blood pressure in eNOS-knockout mice 
(Figure 3F).
Bioactive Peptides in Fraction E of Spirulina
To identify the peptide/peptides responsible for the vascular 
activity of GID-spirulina, fraction E was profiled by UHPLC-
UV-MS/MS. We found 4 abundant spirulina peptides—termed 
SP3, SP4, SP5, SP6—having a percent UV area significantly 
higher than those of the other peaks (Figure 4A). Sequence 
analysis identified the source proteins from which they 
were derived: C-phycocyanin α-chain (YNKFPY, f:60–65, 
830.3962) for SP3; allophycocyanin β-chain (FATGEL, f:31–
35, 636.3119) for SP4; allophycocyanin β-chain (NSLGVPI, 
f:117–123, 698.4026) for SP5; and allophycocyanin α-chain 
(GIVAGDVTPI, f:95–104, 940.5229) for SP6 (Figure 4B). 
Tandem mass spectra are reported in Figure S3.
Interestingly, SP6 was detectable in the serum of mice 
treated with 10 mg/kg of fraction E, a finding indicating that 
the native form of this peptide is resistant to hydrolysis in the 
circulation, allowing it to remain bioavailable (Figure 4C and 
Figure S2).
Characterization of the Vascular and Molecular 
Action of Bioactive Spirulina Peptides
The 4 peptides were then synthesized to obtain sufficient pure 
compounds for the testing of their vascular effects. When used 
on ex vivo mouse mesenteric arteries, only SP5 and SP6 in-
duced significant dose-dependent vasorelaxation, with the lat-
ter developing the stronger effect (maximal relaxation: SP5, 
≈32%; SP6, ≈68%; Figure 4D).
SP5 and SP6 were then selected for in vivo studies in 
which we orally administered a single dose of either 2.5, 5, or 
10 mg/kg of one of the peptides to normotensive mice. Only 
10 mg/kg of SP6 reduced systolic blood pressure, an effect 
that was significant between 2 and 8 hours from administra-
tion, with return to the basal level by 24 hours (Figure 4E). Ex 
vivo evaluation of vascular effects on vessels harvested after 
8 hours from in vivo administration revealed that SP5 was in-
effective in improving acetylcholine-evoked vasorelaxation 
(Figure 4F left), whereas SP6 was effective at the 2 highest 
doses (Figure 4F, right). Western blotting analysis revealed 
Figure 1. Spirulina evokes a dose-dependent vasorelaxation effect through nitric oxide. A, Workflow of in vitro simulated gastrointestinal digestion (GID). 
B, Vascular response of phenylephrine-precontracted mouse mesenteric arteries to increasing doses (2–200 µg/mL) of GID-spirulina (Spx) in the presence 
(E+) or absence of endothelium (E-). C, Inhibition of eNOS (endothelial NO synthase) with N(ω)-nitro-L-arginine methyl ester (L-NAME) abolishes the effect of 
Spx. D, Mesenteric arteries from eNOS-knockout mice (eNOS KO) are refractive to the effects of Spx. Data are mean±SEM of n=7 independent experiments. 
*P<0.05, **P<0.01, ***P<0.001. Veh indicates vehicle.
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that the PI3K/AKT/eNOS pathway was activated in mesen-
teric arteries by administration of SP6 (Figure 4G).
Coherently with previous observations, SP6 failed to 
evoke dose-dependent vasorelaxation of mesenteric arter-
ies harvested from eNOS-knockout mice or from wild-type 
mice when pretreating vessels with L-NAME (Figure 5A and 
Figure S4). Moreover, SP6 failed to reduce blood pressure 
when administered orally to eNOS-knockout mice (Figure 5B 
and Figure S5A).
SP6 Enhances Endothelial Function of Vessels 
Harvested From Hypertensive Animals
We then focused our attention on an experimental model of 
hypertension, namely the spontaneously hypertensive rat 
(SHR), in which endothelial dysfunction is associated with 
high blood pressure. SP6 evoked vasorelaxation of ex vivo 
SHR mesenteric arteries in a dose-dependent manner, albeit 
to a reduced extent with respect to vessels harvested from 
normotensive WKY (Wistar Kyoto) rats (Figure 5C and 5D 
and Figure S6); analogous findings were obtained with ves-
sels harvested from Ang II (angiotensin II)-infused wild-type 
mice, a second model of hypertension (Figure S7).
The characterization of the intracellular pathway at func-
tional and molecular levels using pharmacological inhibitors 
showed that the PI3K/AKT intracellular signaling pathway 
was recruited by SP6 to phosphorylate eNOS, and this was 
necessary to release NO (Figure 5E). That inhibition of eNOS 
abolished SP6-evoked vasodilation in both SHRs and WKY 
rats demonstrated that NO represents the only determinant of 
SP6-evoked relaxation (Figure S6A and S6B; see also results 
in the online-only Data Supplement). An interesting finding 
emerging from the molecular studies on vessels subjected to 
functional analyses is that, although we observed reduced vas-
odilation in vessels from SHRs, SP6 induced an increase of 
eNOS phosphorylation in this animal model compared with 
their relative control rats (Figure 5E).
Thus, we decided to incubate dysfunctional vessels from 
SHRs and evaluate acetylcholine-evoked vasorelaxation. 
Interestingly, SP6 enhanced acetylcholine-evoked vasorelaxation 
in both SHRs and WKY rats, an effect that disappeared upon 
eNOS inhibition (Figure S8). The data so far described show that 
the vascular action of SP6 is characterized by a direct vasore-
laxation effect on constricted vessels and a sensitizing effect on 
acetylcholine-evoked vasorelaxation by potentiating NO release.
NO release was then assessed visually under the micro-
scope with a reagent that becomes fluorescent in the presence 
of NO. SP6 increased the green fluorescence signal selectively 
at the endothelium of wild-type vessels, indicating NO release 
at this level (Figure S9A); similar observations were made on 
SHR and Ang II–infused mouse vessels (Figure S9B–S9D). 
Figure 2. GID (gastrointestinal digestion)-spirulina exerts its vascular effect through the PI3K-AKT-eNOS (endothelial NO synthase) pathway. A, Response of 
phenylephrine-precontracted mouse mesenteric arteries to increasing doses of GID-spirulina (2–200 µg/mL) in the presence of the AMPK inhibitor compound 
C. B, The PI3K inhibitor LY294002 abolishes GID-spirulina–evoked vasorelaxation. C, Also Akt Inhibitor X abolishes GID-spirulina–evoked vasorelaxation. 
Data are mean±SEM of n=7 independent experiments. *P<0.05, **P<0.01, ***P<0.001 vs vehicle (Veh). D, left, Representative immunoblotting conducted on 
extracts of mouse mesenteric artery exposed to GID-spirulina (100 µg/mL) alone or in the presence of either LY294002 or Akt Inhibitor X; middle and right, 
Semiquantitative analyses of phosphorylation levels of phospho-eNOS (endothelial NO synthase) serine 1177; phospho-PI3K (phosphoinositide-3-kinase) 
tyrosine 485; phospho-Akt (serine/threonine kinase Akt) serine 473 (mean±SEM; n=3 independent experiments) and schematic of the spirulina/PI3K/AKT 
pathway leading to release of NO. *P<0.05. SP indicates spirulina peptide.
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In agreement with functional and molecular data, the presence 
of acetylcholine further enhanced SP6-induced endothelial 
fluorescence, indicating potentiation of NO release (Figure 
S9A–S9D). As expected, there was no green fluorescence 
emanating from eNOS-knockout vessels (Figure S9B).
SP6 Exerts an Antihypertensive Action Through a 
NO-Dependent Mechanism
The results obtained in vitro led us to explore the hemody-
namic properties of SP6 in vivo in a hypertensive context. 
Administration of a single oral dose of 10 mg/kg of SP6 to 
SHRs induced a significant decrease (≈43 mm Hg) of blood 
pressure between 2 and 8 hours after gavage (Figure 5F), 
demonstrating that this peptide is active also in a hyperten-
sive context in vivo. The evaluation of serum nitrite levels—a 
well-recognized biomarker of the state of NO metabolism—
showed that there was a dose-dependent increase of this pa-
rameter in SP6-treated SHRs (Figure 5G).
To define the role of NO in the hemodynamic effects of 
the peptide, SP6 was then administered to SHRs after re-
ceiving L-NAME intraperitoneally. As expected, SP6 was 
unable to hinder the blood pressure increase induced by in-
hibition of eNOS (Figure 6A and 6B, left). Moreover, SP6 
reduced blood pressure in SHRs to a much greater degree 
than in normotensive rats. Vascular reactivity studies per-
formed on vessels excised from rats at the time of SP6’s 
maximal effect demonstrated that administration of the pep-
tide protected from endothelial dysfunction because acetyl-
choline-evoked vasorelaxation was significantly enhanced 
(Figure 6A and 6B, right).
Analyses at the molecular level further strengthened our 
findings on the mechanisms induced by spirulina because in 
vessels from rats treated with SP6 the action of acetylcho-
line on eNOS phosphorylation was significantly potentiated 
(Figure 6C). Moreover, SP6 enhanced green fluorescence 
emissions in SHRs and WKY rats, an effect lost in the presence 
Figure 3. Characterization of the vascular effects of spirulina fractions. A, Semi-prep reversed-phase high-performance liquid chromatography UV 
chromatogram showing fractions A–E. B, Response of phenylephrine-precontracted mouse mesenteric arteries to increasing doses (2–200 µg/mL) of GID-
spirulina fractions B–E (n=5). C, Response of phenylephrine-precontracted mouse mesenteric arteries to increasing doses of E in the presence of an eNOS 
(endothelial NO synthase) inhibitor (n=5). D, left, Time course of systolic blood pressure (SBP) in C57BL/6 mice receiving a single oral dose of vehicle (Veh) or 
the indicated GID-spirulina fraction (n=6/group). Arrow indicates time of administration via gavage. Data are mean±SEM. *P<0.05 vs all; right, dose-response 
curves to acetylcholine (Ach; 10−9 M to 10−5 M) of mesenteric arteries excised from mice 8 h after a single oral dose of Veh or the indicated fraction. Values are 
means±SEM of n=6 experiments. *P<0.05 vs all. E, left, time course of SBP in C57BL/6 mice given differing doses of fraction E; right, Dose-response to ACh 
of mesenteric arteries excised at 4 h (n=6/group). *P<0.05 vs Veh; #P<0.05 vs 2.5 mg/kg; §P<0.05 vs 5 mg/kg. F, SBP in wild-type (WT) and eNOS-knockout 
(KO) mice administered Veh. or fraction E (n=5/group). L-NAME indicates N(ω)-nitro-L-arginine methyl ester.
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of L-NAME (Figure 6D). Careful analysis of our data re-
vealed that the acetylcholine-evoked increase in green fluores-
cence was significantly higher in SHRs versus normotensive 
rats, in agreement with molecular studies showing enhanced 
eNOS phosphorylation in the former; in vessels treated with 
SP6, acetylcholine incremented green fluorescence, indicating 
higher NO release (Figure 6D).
Discussion
This study identifies for the first time a novel decameric pep-
tide, generated by simulated GID of spirulina, that induces 
endothelial vasorelaxation in a dose-dependent manner. 
Activation of the PI3K/AKT/eNOS signaling pathway was 
responsible for normalizing blood pressure in experimental 
models of hypertension.
S platensis—a microscopic filamentous blue/green alga 
rediscovered in the 1960s—has garnered increasing attention 
over the past 10 years after the publication of reports on the 
health benefits of its dried biomass, spirulina.8–10 Because of 
a high protein content, spirulina may be a useful substance 
from which bioactive peptides can be obtained. Indeed, 
small tripeptides have been identified—mainly through hy-
drolysis with nonendogenous proteases, such as alcalase11 or 
papain12—that exert an antihypertensive effect by inhibiting 
Ang II signaling and oxidative stress in experimental mod-
els.12,13 However, differently from these studies, we decided 
to process spirulina through simulated human GID, using 
endogenous enzymes that mimic the physiological process. 
In particular, this method provides enormous advantages: 
(1) it generates products that are resistant to digestion after 
Figure 4. Characterization of single peptides isolated from fraction E of spirulina. A, UV and extracted-ion chromatograms of fraction E, revealing the peaks 
indicating the presence of the 4 spirulina peptides (SP)3, SP4, SP5, and SP6 (left), and the MS/MS (tandem mass spectrometry) spectrum of the peptide 
sequence of SP6. B, Chemical structures of the individual SPs present in fraction E. C, Selected reaction monitoring of the presence of SP6 in mouse serum 
after oral administration of 10 mg/kg of fraction E. D, Response of phenylephrine-precontracted mouse mesenteric arteries to increasing doses of SP3, 
SP4, SP5, and SP6 (n=5). *P<0.05, **P<0.01 vs SP3 and SP4; #P<0.05, ##P<0.01 vs SP5. E, Time course of systolic blood pressure (SBP) in C57BL/6 mice 
administered vehicle (Veh) or different doses of the indicated peptide. Arrow indicates time of administration via gavage. Data are mean±SEM of n=6/group. 
F, left and right, Dose-response curves to acetylcholine (ACh) of mesenteric arteries excised from mice 8 h after administration of SP5 (left) or SP6 (right) 
given at the indicated dosage (n=6/group). *P<0.05, **P<0.01 vs Veh; #P<0.05 vs 2.5 mg/kg. G, left, Representative immunoblottings conducted on extracts 
of mouse mesenteric arteries harvested 8 h after administration of SP6 at different doses; right, Semiquantitative densitometric analyses of phosphorylation 
levels of phospho-eNOS (endothelial NO synthase) serine 1177; phospho-PI3K (phosphoinositide-3-kinase) tyrosine 485; phospho-Akt (serine/threonine 
kinase Akt) serine 473. Data are the mean±SEM of 3 independent experiments. *P<0.05. eNOS indicates endothelial NO synthase.
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oral administration;7 (2) it provides information on the prod-
ucts’ release sites; and (3) more-potent bioactive products are 
obtained.14
In the first part of our study, we demonstrate that GID-
spirulina directly induces vasodilation of mouse resistance arter-
ies, an important vascular district involved in blood pressure 
regulation. This action was dependent upon the activation of 
eNOS in the endothelium because vascular effects were com-
pletely lost in eNOS-knockout mice. However, pharmacological 
inhibition of AMPK—an important sensor of cellular energy 
status and a key molecule involved in metabolic control that 
has been reported to be efficiently activated by several natural 
compounds15,16—did not influence the vasorelaxant properties of 
GID-spirulina. In contrast, we found that eNOS was activated 
by phosphorylation on Ser1177 through a PI3K/AKT pathway.
Using a 2-stage approach, we divided whole GID-spirulina 
matrix into 5 fractions (A to E) to identify the most bioactive 
portion. Only fraction E evoked NO-dependent vasorelaxation 
of ex vivo vessels and reduced blood pressure in mice. Of note, 
a low dose of fraction E did not inﬂuence blood pressure home-
ostasis but was still able to enhance NO-mediated vasorelax-
ation, indicating that its administration at lower doses may help 
contain vascular diseases without influencing blood pressure.
These findings led us to hypothesize that fraction E con-
tained stable peptides that survived GID and that once ab-
sorbed exerted a direct vascular effect. Indeed, through a 
Figure 5. Molecular mechanism and hemodynamic effects evoked by SP6 (spirulina peptide 6). A, Response of phenylephrine-precontracted mesenteric 
arteries harvested from wild-type (WT) and eNOS (endothelial NO synthase)-knockout (KO) mice to increasing doses of SP6, the former also in the presence 
of the eNOS inhibitor N(ω)-nitro-L-arginine methyl ester (L-NAME). *P<0.05, **P<0.01 vs all. B, Representative intrafemoral blood pressure (BP) traces (1-min 
intervals) measured in C57BL/6 (WT) and eNOS KO mice receiving vehicle (Veh) or 10 mg/kg of SP6, at different times after the administration by gavage 
(indicated by an arrow). C and D, Response of phenylephrine-precontracted mesenteric arteries harvested from normotensive WKY (Wistar Kyoto) rats (C) 
and spontaneously hypertensive rats (SHR; D) to increasing doses of SP6 in the presence of a PI3K inhibitor (LY294002), an AKT inhibitor (Akt inh), or an 
eNOS inhibitor (L-NAME). (n=7) *P<0.05, **P<0.01, ***P<0.001 vs vehicle. E, left, Representative immunoblottings conducted on extracts of mesenteric 
arteries, harvested from hypertensive and normotensive rats, exposed to SP6 (100 µg/mL) alone or in the presence of LY294002, AKT Inhibitor X, or L-NAME; 
right, Semiquantitative analyses of phosphorylation of phospho-eNOS (endothelial NO synthase) serine 1177; phospho-PI3K (phosphoinositide-3-kinase) 
tyrosine 485; phospho-Akt (serine/threonine kinase Akt) serine 473. Data are mean±SEM of 3 independent experiments. *P<0.05 vs all, #P<0.05 vs WKY. F, 
Time course of systolic blood pressure (SBP) in SHRs receiving vehicle or different doses of SP6. Values are the means±SEM. (n=5/group). *P<0.05, **P<0.05 
vs all. G, Serum concentration of stable NO metabolites in SHRs treated with vehicle or different doses of SP6. n=6 per group. *P<0.05.
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chemical approach, we isolated 4 different spirulina peptides 
from fraction E, finding that SP6 was unique in its ability to 
activate the endothelial NO machinery. Of note, the quanti-
fication of the circulating level of SP6 after oral administra-
tion of fraction E to mice revealed that the native form of this 
decapeptide was present, clearly indicating that the peptide is 
bioavailable and resists further hydrolysis in the blood.
It is well known that hypertensive patients have a defect in 
the endothelium-dependent NO system; this contributes signif-
icantly to increased vascular resistance in the basal condition 
and to impairment of endothelium-dependent vasorelaxation. 
Moreover, oral administration of SP6 to SHRs—one of the 
best animal models reproducing the alterations seen in human 
hypertension—increased serum nitrite levels and exerted an 
antihypertensive effect. In addition, results obtained in vivo 
on inhibition of eNOS clearly demonstrated that the hemody-
namic action of SP6 is mediated by NO. Thus, the antihyper-
tensive effect observed in hypertensive rats could be ascribed 
to SP6 directly inducing enhancement of endothelial function 
and, hence, vasorelaxation.
In conclusion, the health-enhancing potential and safety 
profile of SP6 designate this stable bioactive peptide—which 
is obtainable from a complex natural matrix—as an interesting 
candidate for future studies on the prevention of cardiovas-
cular diseases associated with NO dysregulation.
Study Limitations
The data presented here demonstrate acute, beneficial cardi-
ovascular effects of SP6, but clearly, more studies are needed 
to clarify whether its effects can also be extended to chronic 
conditions. Preliminary analysis of serum in animals treated 
with 10 mg/kg of fraction E revealed the presence of an intact 
decapeptide, the concentration of which was obviously low, 
but the analysis did not take into account metabolization and 
excretion processes. Characterization of the tissue distribution 
and pharmacokinetics of SP6 will be the aim of future studies 
necessary to fully understand the effects evoked by the peptide.
Perspectives
The current study provides new information on the po-
tential effects of spirulina on cardiovascular homeostasis. 
Moreover, the identification of a single bioactive pep-
tide from the plethora of molecules generated from simu-
lated GID of spirulina, and the description of its efficacy 
in vivo, opens a new scenario in the development of non-
pharmacological adjuvants that may be combined with 
Figure 6. SP6 (spirulina peptide 6) reduces blood pressure in normotensive and hypertensive rats through a NO-dependent mechanism. A and B, left, 
Systolic blood pressure (SBP) in normotensive WKY (Wistar Kyoto) rats (A) and in spontaneously hypertensive rats (SHRs; B) administered vehicle (Veh), 
10 mg/kg of SP6 alone, or SP6 30 min after pretreatment with L-NAME (75 mg/kg IP). Values are means±SEM (n=6 per group). *P<0.05 vs all; #P<0.05 
vs Veh; right, Response of ex vivo phenylephrine-precontracted rats mesenteric arteries to increasing doses of acetylcholine, excised 8 h from in vivo 
treatments. *P<0.05 vs all; #P<0.05 vs Veh. C, left, Representative immunoblots conducted on extracts of mesenteric arteries excised from rats after 8 h 
from in vivo treatment; right, Semiquantitative analyses of phosphorylation levels of phospho-eNOS (endothelial NO synthase) serine 1177; phospho-PI3K 
(phosphoinositide-3-kinase) tyrosine 485; phospho-Akt (serine/threonine kinase Akt) serine 473. Data are mean±SEM of 3 independent experiments. *P<0.05, 
§P<0.05 vs WKY+Veh, #P<0.05 vs WKY+SP6. D, Representative micrographs of DAF-FM fluorescent signal in mesenteric arteries excised from in vivo-
treated rats (Veh, SP6 alone, or N(ω)-nitro-L-arginine methyl ester [L-NAME] then SP6) stimulated with acetylcholine (Ach; 10–5 M). Inset: images merged with 
sections counterstained with hematoxylin-eosin. Scale bar, 100 µm. The graph gives mean fluorescence intensity of fluorescence measurements. Data are 
mean±SEM of 5 independent experiments. *P<0.05.
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pharmacological compounds to improve endothelial func-
tion and control blood pressure.
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What Is New?
•	We used a peptidomic approach comprising a model of in vitro gastroin-
testinal digestion, fractionation, and high-resolution mass spectrometry 
of the dried biomass of Spirulina platensis to identify a single biologically 
active peptide–SP6 (spirulina peptide 6).
•	SP6 is a novel, decameric, spirulina-derived peptide that modulates en-
dothelial function to increase the production of NO; of note, it is effective 
when administered orally in reducing blood pressure in animal models 
of hypertension.
What Is Relevant?
•	The identification of bioactive peptides such as spirulina peptide 6 
[GIVAGDVTPI] that modulate endothelial function and blood pressure 
could lead to the development of novel natural coadjutants to the phar-
macological treatment of hypertension.
•	The existence of doses of spirulina peptide 6 that do not modulate blood 
pressure but are still able to enhance endothelial NO-mediated vasore-
laxation strongly suggests that the peptide could be considered for novel 
natural therapeutic approaches to contain vascular diseases associated 
with NO dysfunction, independently from a hemodynamic effect.
Summary
Food-derived materials are usually extremely complex, containing 
hundreds of compounds, and, thus, represent a challenging task. 
This is compounded for proteins because hydrolysis by endopro-
teases releases large numbers of peptides of differing molecular 
weights. Here, we used a complex, multistep, mass-spectrometry-
assisted platform to isolate the most bioactive peptide (spirulina 
peptide 6) in a spirulina digest. We identified its exact amino acid 
sequence and defined its action on endothelial function and blood 
pressure, finding that it acted through a PI3K/AKT/eNOS (endothe-
lial NO synthase)-dependent pathway. The identification of spiru-
lina peptide 6 may open the door to the development of new natural 
therapies aimed at containing the incidence of arterial hypertension 
and vascular diseases.
Novelty and Significance
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